<?xml version="1.0" encoding="ISO-8859-1"?><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
<front>
<journal-meta>
<journal-id>1727-897X</journal-id>
<journal-title><![CDATA[MediSur]]></journal-title>
<abbrev-journal-title><![CDATA[Medisur]]></abbrev-journal-title>
<issn>1727-897X</issn>
<publisher>
<publisher-name><![CDATA[Universidad de Ciencias Médicas de Cienfuegos, Centro Provincial de Ciencias Médicas, Provincia de Cienfuegos.]]></publisher-name>
</publisher>
</journal-meta>
<article-meta>
<article-id>S1727-897X2023000100083</article-id>
<title-group>
<article-title xml:lang="es"><![CDATA[Fármacovigilancia de la carbamazepina en el Policlínico Marta Abreu. Santa Clara, 2022]]></article-title>
<article-title xml:lang="en"><![CDATA[Pharmacovigilance of carbamazepine at the Marta Abreu Polyclinic. Santa Clara, 2022]]></article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Ruíz López]]></surname>
<given-names><![CDATA[Adrián]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
<xref ref-type="aff" rid="Aaf"/>
</contrib>
</contrib-group>
<aff id="Af1">
<institution><![CDATA[,Policlínico docente Marta Abreu  ]]></institution>
<addr-line><![CDATA[Santa Clara ]]></addr-line>
<country>Cuba</country>
</aff>
<pub-date pub-type="pub">
<day>00</day>
<month>02</month>
<year>2023</year>
</pub-date>
<pub-date pub-type="epub">
<day>00</day>
<month>02</month>
<year>2023</year>
</pub-date>
<volume>21</volume>
<numero>1</numero>
<fpage>83</fpage>
<lpage>89</lpage>
<copyright-statement/>
<copyright-year/>
<self-uri xlink:href="http://scielo.sld.cu/scielo.php?script=sci_arttext&amp;pid=S1727-897X2023000100083&amp;lng=en&amp;nrm=iso"></self-uri><self-uri xlink:href="http://scielo.sld.cu/scielo.php?script=sci_abstract&amp;pid=S1727-897X2023000100083&amp;lng=en&amp;nrm=iso"></self-uri><self-uri xlink:href="http://scielo.sld.cu/scielo.php?script=sci_pdf&amp;pid=S1727-897X2023000100083&amp;lng=en&amp;nrm=iso"></self-uri><abstract abstract-type="short" xml:lang="es"><p><![CDATA[RESUMEN  Fundamento:  en la práctica, el término estupefaciente se aplica a las especialidades farmacéuticas que contienen principios activos que actúan sobre el sistema nervioso central modificándolo y a las fórmulas magistrales con los mismos principios activos.  Objetivo:  caracterizar clínica y epidemiológicamente los pacientes que consumen carbamazepina en un área de salud del municipio de Santa Clara.  Métodos:  estudio descriptivo, transversal, en pacientes que consumen carbamazepina, pertenecientes al Policlínico Docente Marta Abreu, en el período del 1 de enero de 2021 al 1 de abril de 2022. Se incluyeron 209 pacientes y se midieron las siguientes variables: edad, sexo, número de pacientes según diagnósticos, número de pacientes según nuevos protocolos y tiempo de consumo del tratamiento.  Resultados:  predominó el grupo de edades de 51 a 60 con 43 pacientes (20,5 %), dentro de este grupo el sexo femenino (11,0 % del total); el diagnóstico predominante fue la epilepsia generalizada (93 pacientes). Predominó el sexo femenino, con 59 pacientes, y en ellas se encontró la mayor cantidad de expedientes vencidos, con un total de 16. Según nuevos protocolos, prevalecieron los pacientes con diagnóstico de neuralgia trigeminal, glosofaríngeo o facial (7 pacientes). En cuanto al tiempo de consumo predominaron los pacientes con igual diagnóstico a los anteriores y trastorno del comportamiento debido a enfermedad médica, ambos grupos con tratamientos de hasta tres años.  Conclusiones:  es importante el conocimiento sobre el uso y abuso de los estupefacientes así como mantener actualizado a todo el personal sanitario para lograr el óptimo control sobre estas sustancias.]]></p></abstract>
<abstract abstract-type="short" xml:lang="en"><p><![CDATA[ABSTRACT   Background:  in practice, the term narcotic is applied to pharmaceutical specialties that contain active ingredients that act on the central nervous system, modifying it, and to master formulas with the same active ingredients.  Objective:  to characterize clinically and epidemiologically the patients who consume carbamazepine in a health area of the Santa Clara municipality.  Methods:  descriptive, cross-sectional study in patients consuming carbamazepine, belonging to the Marta Abreu Teaching Polyclinic, from January the 1st, 2021 to April the 1st, 2022. 209 patients were included and the following variables were measured: age, sex, number of patients according to diagnoses, number of patients according to new protocols and time of consumption of the treatment.  Results:  the age group from 51 to 60 predominated with 43 patients (20.5%), within this group the female sex (11.0% of the total); the predominant diagnosis was generalized epilepsy with a total of 93 patients. The female sex predominated with a total of 59 patients and in them the largest number of expired files was found, with a total of 16. According to new protocols, patients with a diagnosis of trigeminal, glossopharyngeal or facial neuralgia (7 patients) predominated. Regarding the time of consumption, patients with the same diagnosis as the previous ones and behavioral disorder due to a medical illness predominated, both groups with treatments of up to three years.  Conclusions:  knowledge about the use and abuse of narcotic drugs is important, as well as keeping all health personnel updated to achieve optimal control over these substances.]]></p></abstract>
<kwd-group>
<kwd lng="es"><![CDATA[carbamazepina]]></kwd>
<kwd lng="es"><![CDATA[farmacovigilancia]]></kwd>
<kwd lng="es"><![CDATA[farmacoepidemiología]]></kwd>
<kwd lng="en"><![CDATA[carbamazepine]]></kwd>
<kwd lng="en"><![CDATA[pharmacovigilance]]></kwd>
<kwd lng="en"><![CDATA[pharmacohepidemiology]]></kwd>
</kwd-group>
</article-meta>
</front><back>
<ref-list>
<ref id="B1">
<label>1</label><nlm-citation citation-type="book">
<collab>Organización de Naciones Unidas</collab>
<source><![CDATA[Convención Única de 1961 sobre estupefacientes]]></source>
<year>1961</year>
<publisher-loc><![CDATA[Washington ]]></publisher-loc>
<publisher-name><![CDATA[ONU]]></publisher-name>
</nlm-citation>
</ref>
<ref id="B2">
<label>2</label><nlm-citation citation-type="book">
<collab>Escuela Andaluza de Salud Pública</collab>
<source><![CDATA[Estupefacientes: prescripción y dispensación]]></source>
<year>1994</year>
<publisher-loc><![CDATA[Granada ]]></publisher-loc>
<publisher-name><![CDATA[CADIME]]></publisher-name>
</nlm-citation>
</ref>
<ref id="B3">
<label>3</label><nlm-citation citation-type="book">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Mc Namara]]></surname>
<given-names><![CDATA[JO.]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Pharmacotherapy of the epilepsies]]></article-title>
<collab>Goodman &amp; Gilman</collab>
<source><![CDATA[The pharmacological basis of therapeutics]]></source>
<year>2016</year>
<edition>11</edition>
<page-range>557-93</page-range><publisher-loc><![CDATA[México ]]></publisher-loc>
<publisher-name><![CDATA[McGraw-Hill Interamericana]]></publisher-name>
</nlm-citation>
</ref>
<ref id="B4">
<label>4</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Nieto Barrera]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Evolución del tratamiento antiepiléptico desde los bromuros a la farmacogenética]]></article-title>
<source><![CDATA[Vox Paediatrica Behavior]]></source>
<year>2011</year>
<volume>XVIII</volume>
<numero>1</numero>
<issue>1</issue>
<page-range>30-48</page-range></nlm-citation>
</ref>
<ref id="B5">
<label>5</label><nlm-citation citation-type="book">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Lorenzo]]></surname>
<given-names><![CDATA[P]]></given-names>
</name>
<name>
<surname><![CDATA[Moreno]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Lizasoain]]></surname>
<given-names><![CDATA[I]]></given-names>
</name>
<name>
<surname><![CDATA[Leza]]></surname>
<given-names><![CDATA[JC]]></given-names>
</name>
<name>
<surname><![CDATA[Moro]]></surname>
<given-names><![CDATA[MA]]></given-names>
</name>
<name>
<surname><![CDATA[Portolés]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Velázquez]]></surname>
<given-names><![CDATA[B.]]></given-names>
</name>
</person-group>
<source><![CDATA[Farmacología Básica y Clínica]]></source>
<year>2018</year>
<edition>18</edition>
<page-range>243-61</page-range><publisher-loc><![CDATA[México ]]></publisher-loc>
<publisher-name><![CDATA[Editorial Médica Panamericana]]></publisher-name>
</nlm-citation>
</ref>
<ref id="B6">
<label>6</label><nlm-citation citation-type="book">
<collab>American Society of Health</collab>
<source><![CDATA[Carbamazepina]]></source>
<year>2009</year>
<publisher-loc><![CDATA[Maryland ]]></publisher-loc>
<publisher-name><![CDATA[US National Library Medicine]]></publisher-name>
</nlm-citation>
</ref>
<ref id="B7">
<label>7</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Roussó]]></surname>
<given-names><![CDATA[T]]></given-names>
</name>
<name>
<surname><![CDATA[Cordero]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Rodríguez]]></surname>
<given-names><![CDATA[Y]]></given-names>
</name>
<name>
<surname><![CDATA[Suárez]]></surname>
<given-names><![CDATA[I]]></given-names>
</name>
<name>
<surname><![CDATA[Alonso]]></surname>
<given-names><![CDATA[E]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Aspectos históricos del tratamiento farmacológico de la epilepsia]]></article-title>
<source><![CDATA[Rev Ecuat Neurol Behavior]]></source>
<year>2011</year>
<volume>12</volume>
<numero>1-2</numero>
<issue>1-2</issue>
<page-range>15-9</page-range></nlm-citation>
</ref>
<ref id="B8">
<label>8</label><nlm-citation citation-type="book">
<collab>Food and Drugs Administration (FDA).</collab>
<source><![CDATA[Carbamazepine]]></source>
<year>2017</year>
<publisher-loc><![CDATA[Maryland ]]></publisher-loc>
<publisher-name><![CDATA[FDA]]></publisher-name>
</nlm-citation>
</ref>
<ref id="B9">
<label>9</label><nlm-citation citation-type="book">
<collab>Ministerio de Justicia</collab>
<source><![CDATA[Gaceta Oficial de la República de Cuba. No. 22. Nuevo protocolo para la prescripción y dispensarización de fármacos con efectos similares a drogas]]></source>
<year>2022</year>
<publisher-loc><![CDATA[La Habana ]]></publisher-loc>
<publisher-name><![CDATA[Ministerio de Justicia]]></publisher-name>
</nlm-citation>
</ref>
<ref id="B10">
<label>10</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Rodríguez Ganen]]></surname>
<given-names><![CDATA[O]]></given-names>
</name>
<name>
<surname><![CDATA[Alonso Carbonell]]></surname>
<given-names><![CDATA[L]]></given-names>
</name>
<name>
<surname><![CDATA[Yera Alós]]></surname>
<given-names><![CDATA[IB]]></given-names>
</name>
<name>
<surname><![CDATA[García Milián]]></surname>
<given-names><![CDATA[AJ.]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Caracterización del patrón de prescripción de Carbamazepina: provincias seleccionadas de Cuba, año 2005.]]></article-title>
<source><![CDATA[Rev Cubana Farm]]></source>
<year>2006</year>
<volume>40</volume>
<numero>1</numero>
<issue>1</issue>
</nlm-citation>
</ref>
<ref id="B11">
<label>11</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Martínez Leiva]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Rivero León]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Del Pozo Nistal]]></surname>
<given-names><![CDATA[Y.]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Uso y abuso en la prescripción de la Carbamazepina en el Área Sur de Morón.]]></article-title>
<source><![CDATA[MEDICIEGO]]></source>
<year>2012</year>
<volume>18</volume>
<numero>No especial</numero>
<issue>No especial</issue>
</nlm-citation>
</ref>
<ref id="B12">
<label>12</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Zapata]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Perdomo]]></surname>
<given-names><![CDATA[I]]></given-names>
</name>
<name>
<surname><![CDATA[Vergel]]></surname>
<given-names><![CDATA[G]]></given-names>
</name>
<name>
<surname><![CDATA[Salazar]]></surname>
<given-names><![CDATA[LE.]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Utilización de antiepilépticos en un Hospital General de Ciudad de La Habana]]></article-title>
<source><![CDATA[Rev Cub Farm]]></source>
<year>2002</year>
<volume>36</volume>
<numero>3</numero>
<issue>3</issue>
</nlm-citation>
</ref>
<ref id="B13">
<label>13</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Lores]]></surname>
<given-names><![CDATA[D]]></given-names>
</name>
<name>
<surname><![CDATA[Lazo]]></surname>
<given-names><![CDATA[Y]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Prescripción de Carbamazepina en la farmacia principal municipal Santiago de Cuba]]></article-title>
<source><![CDATA[Rev Org Farm Iberoam]]></source>
<year>2006</year>
<volume>16</volume>
<numero>2</numero>
<issue>2</issue>
<page-range>25-33</page-range></nlm-citation>
</ref>
<ref id="B14">
<label>14</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Quijano]]></surname>
<given-names><![CDATA[AL]]></given-names>
</name>
<name>
<surname><![CDATA[Montes]]></surname>
<given-names><![CDATA[MJ]]></given-names>
</name>
<name>
<surname><![CDATA[Retamoso]]></surname>
<given-names><![CDATA[I.]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Tratamiento del dolor neuropático]]></article-title>
<source><![CDATA[Arch Med Intern]]></source>
<year>2010</year>
<volume>32</volume>
<numero>1</numero>
<issue>1</issue>
<page-range>17-21</page-range></nlm-citation>
</ref>
<ref id="B15">
<label>15</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Tinoco Samos]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Córdova Pérez]]></surname>
<given-names><![CDATA[N]]></given-names>
</name>
<name>
<surname><![CDATA[Arenas Téllez]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Vargas Girón]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Zárate]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Hernández Valencia]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Mejoría clínica de la neuropatía diabética con Carbamazepina o Diclofenaco]]></article-title>
<source><![CDATA[Revista Médica del IMSS]]></source>
<year>2013</year>
<volume>51</volume>
<numero>5</numero>
<issue>5</issue>
<page-range>96-501</page-range></nlm-citation>
</ref>
<ref id="B16">
<label>16</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Marson]]></surname>
<given-names><![CDATA[AG]]></given-names>
</name>
<name>
<surname><![CDATA[Williamson]]></surname>
<given-names><![CDATA[PR]]></given-names>
</name>
<name>
<surname><![CDATA[Hutton]]></surname>
<given-names><![CDATA[JL]]></given-names>
</name>
<name>
<surname><![CDATA[Clough]]></surname>
<given-names><![CDATA[HE]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Carbamazepine versus Valproate monotherapy for epilepsy]]></article-title>
<collab>Chadwick DW Marson A</collab>
<source><![CDATA[The Cochrane Database of Systematic Reviews]]></source>
<year>2000</year>
<numero>3</numero>
<issue>3</issue>
<page-range>CD001030</page-range></nlm-citation>
</ref>
<ref id="B17">
<label>17</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[García Hernández]]></surname>
<given-names><![CDATA[MG]]></given-names>
</name>
<name>
<surname><![CDATA[Sánchez Rodríguez]]></surname>
<given-names><![CDATA[JP]]></given-names>
</name>
<name>
<surname><![CDATA[Tenopala Villegas]]></surname>
<given-names><![CDATA[S.]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Neuralgia del trigémino]]></article-title>
<source><![CDATA[An Med Mex]]></source>
<year>2012</year>
<volume>57</volume>
<numero>1</numero>
<issue>1</issue>
<page-range>39-47</page-range></nlm-citation>
</ref>
<ref id="B18">
<label>18</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Finzen]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Carbamazepina en el tratamiento de la manía y como profilaxis de las recidivas de los trastornos maníaco-depresivos]]></article-title>
<source><![CDATA[Neuropsicofarmacol Clín]]></source>
<year>2007</year>
<volume>2</volume>
<numero>8</numero>
<issue>8</issue>
<page-range>25-32</page-range></nlm-citation>
</ref>
</ref-list>
</back>
</article>
